CN

Drug Conjugates for Global Patients

About MediLink

Drug Conjugates for Global Patients

About MediLink

Business

Focus on the ADC field, promote technology iteration and product development, and establish technology and product advantages

About MediLink

Medilink Therapeutics focuses on developing internationally competitive drug conjugates, as well as the latest generation of technologies and products with independent intellectual property rights and better therapeutic windows, to serve the unmet clinical needs. It strives to continuously upgrade technologies, establish diverse technology platforms for drug conjugates, and expand into new disease areas to serve global patients.

Learn more

Management Team

Established by a senior ADC team, covering the entire ADC process

Tony Xue

Chairman, Founder & CEO

PhD in Developmental Biology from Shandong Agricultural University, Sichuan Province "Thousand Talents Program", presided over a number of major special projects in the 12th and 13th Five-Year Plan

Jiaqiang Cai

Co-founder & CSO

Jiaqiang Cai, PhD, currently serves as Chief Scientific Officer and on the Board of Directors.

Joey Xiao

Co-founder & COO

PhD in Developmental Biology from Shandong Agricultural University, Sichuan Province "Thousand Talents Program", presided over a number of major special projects in the 12th and 13th Five-Year Plan

Pantner

With the continuous development of the company, we have won the favor of many partners